These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 36091837)

  • 41. Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments.
    Kawashiri SY; Shimizu T; Sato S; Morimoto S; Kawazoe Y; Sumiyoshi R; Hosogaya N; Fukushima C; Yamamoto H; Kawakami A
    Medicine (Baltimore); 2020 Jul; 99(30):e21151. PubMed ID: 32791688
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System.
    Bhardwaja B; Klocke S; Ekinci E; Jackson A; Kono S; Olson KL
    BioDrugs; 2022 Jan; 36(1):1-11. PubMed ID: 34817847
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK.
    Tarallo M; Onishchenko K; Alexopoulos ST
    J Med Econ; 2019 Nov; 22(11):1162-1170. PubMed ID: 31373527
    [No Abstract]   [Full Text] [Related]  

  • 44. An Update on Anti-TNF Biosimilar Switching-Real-World Clinical Effectiveness and Safety.
    Meade S; Squirell E; Hoang TT; Chow J; Rosenfeld G
    J Can Assoc Gastroenterol; 2024 Feb; 7(1):30-45. PubMed ID: 38314175
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.
    McKinnon RA; Cook M; Liauw W; Marabani M; Marschner IC; Packer NH; Prins JB
    BioDrugs; 2018 Feb; 32(1):27-52. PubMed ID: 29344876
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry.
    Nabi H; Hendricks O; Jensen DV; Loft AG; Pedersen JK; Just SA; Danebod K; Munk HL; Kristensen S; Manilo N; Colic A; Linauskas A; Thygesen PH; Christensen LB; Kalisz MH; Lomborg N; Chrysidis S; Raun JL; Andersen M; Mehnert F; Krogh NS; Hetland ML; Glintborg B
    RMD Open; 2022 Nov; 8(2):. PubMed ID: 36418087
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.
    Cohen HP; Blauvelt A; Rifkin RM; Danese S; Gokhale SB; Woollett G
    Drugs; 2018 Mar; 78(4):463-478. PubMed ID: 29500555
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System.
    Jourdain H; Hoisnard L; Sbidian E; Zureik M
    RMD Open; 2024 Mar; 10(1):. PubMed ID: 38453213
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review.
    Hillhouse E; Mathurin K; Bibeau J; Parison D; Rahal Y; Lachaine J; Beauchemin C
    Adv Ther; 2022 Jan; 39(1):455-487. PubMed ID: 34780028
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review.
    García-Beloso N; Altabás-González I; Samartín-Ucha M; Gayoso-Rey M; De Castro-Parga ML; Salgado-Barreira Á; Cibeira-Badia A; Piñeiro-Corrales MG; González-Vilas D; Pego-Reigosa JM; Martínez-López de Castro N
    Br J Clin Pharmacol; 2022 Feb; 88(4):1529-1550. PubMed ID: 34622969
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies.
    Cohen HP; Hachaichi S; Bodenmueller W; Kvien TK; Danese S; Blauvelt A
    BioDrugs; 2022 Sep; 36(5):625-637. PubMed ID: 35881304
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective.
    Milassin Á; Fábián A; Molnár T
    Therap Adv Gastroenterol; 2019; 12():1756284819842748. PubMed ID: 31019554
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting.
    Baker JF; Bakewell C; Dikranian A; Lam G; O'Brien J; Moore PC; Yu M; Hur P; Masri KR
    Rheumatol Ther; 2024 Jun; 11(3):841-853. PubMed ID: 38507187
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends.
    Car E; Vulto AG; Houdenhoven MV; Huys I; Simoens S
    Front Pharmacol; 2023; 14():1151764. PubMed ID: 37153785
    [No Abstract]   [Full Text] [Related]  

  • 55. An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch.
    Luber RP; O'Neill R; Singh S; Sharma E; Cunningham G; Honap S; Meade S; Ray S; Anderson SH; Mawdsley J; Sanderson JD; Samaan MA; Arkir Z; Irving PM
    Aliment Pharmacol Ther; 2021 Sep; 54(5):678-688. PubMed ID: 34223654
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety of switching between rituximab biosimilars in onco-hematology.
    Urru SAM; Spila Alegiani S; Guella A; Traversa G; Campomori A
    Sci Rep; 2021 Mar; 11(1):5956. PubMed ID: 33727667
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.
    Inotai A; Prins CPJ; Csanádi M; Vitezic D; Codreanu C; Kaló Z
    Expert Opin Biol Ther; 2017 Aug; 17(8):915-926. PubMed ID: 28650704
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden.
    Di Giuseppe D; Lindstrom U; Bower H; Delcoigne B; Frisell T; Chatzidionysiou K; Sjöwall C; Lindqvist E; Askling J
    Rheumatology (Oxford); 2022 Aug; 61(9):3596-3605. PubMed ID: 34919663
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and Effectiveness of Multiple Switching Between Originators and Biosimilars: Literature Review and Status Report on Interchangeability.
    Lasala R; Abrate P; Zovi A; Santoleri F
    Ther Innov Regul Sci; 2023 Mar; 57(2):352-364. PubMed ID: 36322326
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.
    Feagan BG; Lam G; Ma C; Lichtenstein GR
    Aliment Pharmacol Ther; 2019 Jan; 49(1):31-40. PubMed ID: 30411382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.